Company intelligence / Profile preview

Altos Biologics

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

ALT-L9 (aflibercept biosimilar) completed a global Phase III trial with >400 participants across 12 countries; EMA marketing application submitted July 2024; aiming for EU approval aligned with patent expiry in 2025. Results showed comparable efficacy, safety, and immunogenicity to aflibercept in wAMD, measured by best-corrected visual acuity improvement.

Therapeutic areas: Ophthalmology
Modalities: BiosimilarFusion protein
Industry: Biotech

Partnerships

Strategic international funding and licensing negotiations in progress for ALT-L9 distribution, including expectation for deals in Korea and globally

Beyond the preview

Go deeper on Altos Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altos Biologics.

Explore the full profile